Dana Aftab sold $2.1M of Exelixis (EXEL)

Executed Feb 24, disclosed Feb 26, 2 days later.

Value, as filed

$2.1M

47,918 sh × $44.50

Executed

Feb 24

the trade date, as filed

Disclosed

Feb 26

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

DA Dana Aftab EVP, Research and Development profile →

Dana Aftab (EVP, Research and Development) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in Exelixis, Inc. (EXEL). The largest single filing was $2.2M of EXEL (43,451 sh × $50.35, as filed), executed May 26.

The name

EXEL Exelixis, Inc. EXEL · Healthcare · 53 filings in 24 months ticker →

Healthcare · Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat c…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Dana Aftab in EXEL

EXELSALE Exelixis, Inc. $2.2M
43,451 sh × $50.35
Exec May 26
Filed May 28 · 5:30 PM ET EXELSALE Exelixis, Inc. $1.3M
29,873 sh × $44.35
Exec Feb 19
Filed Feb 23 · 5:30 PM ET EXELSALE Exelixis, Inc. $2.1M
48,383 sh × $42.50
Exec Nov 11 2025
Filed Nov 13 2025 · 5:30 PM ET EXELSALE Exelixis, Inc. $992K
26,987 sh × $36.75
Exec Feb 24 2025
Filed Feb 26 2025 · 5:30 PM ET EXELSALE Exelixis, Inc. $3.4M
96,986 sh × $35.00
Exec Nov 5 2024
Filed Nov 7 2024 · 5:30 PM ET